ARL10: A Potential Drug Target and Biomarker (G285598)

Target Name: ARL10

NCBI ID: G285598

ARL10

ARL10: A Potential Drug Target and Biomarker

Introduction

ARL10 (ADP ribosylation factor like GTPase 10) is a protein that plays a critical role in various cellular processes, including cell signaling, DNA replication, and protein synthesis. It is a key player in the transcription process of the swallow gene, involved in gene expression and Regulation. ARL10 is upregulated in a variety of cancers and plays an important role in tumor progression. At the same time, ARL10 is also considered an effective target for the treatment of certain types of cancer. This article will elaborate on the potential role of ARL10 in drug development and tumor treatment, and explore the application prospects of ARL10 as a biomarker.

Functions and functions of ARL10

ARL10 is a GTPase with phosphorylation-dependent activity in cells. ARL10 binds to the DNA template and, under the catalysis of DNA polymerase I (DNAP), phosphorylates the four free nucleotides and the 3' end of the DNA template chain to form four types of DNA nucleotide phosphodiesters. key. This process provides the necessary enzymatic activity for DNA replication and also provides the basis for gene expression and regulation.

During tumor progression, the expression level of ARL10 changes and is up- or down-regulated. Overexpression of ARL10 is closely related to adverse prognostic events such as tumor occurrence, development, invasion, and metastasis. Studies have found that the expression level of ARL10 is positively correlated with the prognosis of various cancers, such as lung cancer, liver cancer, breast cancer, etc. In addition, the expression level of ARL10 is also related to the invasion and metastasis ability of tumors. Therefore, ARL10 has high clinical value in tumor treatment.

Drug Discovery

In order to inhibit the role of ARL10 in tumor treatment, researchers began to look for drugs with the activity of inhibiting ARL10 phosphorylation. Currently, some drugs that inhibit the phosphorylation activity of ARL10 are in the clinical research stage, such as ARL10-specific inhibitors. These drugs inhibit the phosphorylation activity of ARL10 by blocking the binding of ARL10 to DNA templates, thereby inhibiting the role of ARL10 in tumor treatment.

Biomarkers

The role of ARL10 in tumor treatment makes it a potential biomarker. By detecting the expression level of ARL10 in tumor tissue, the efficacy of tumor treatment can be evaluated and the progression of the tumor can be predicted. In addition, the expression level of ARL10 can also be used as an important indicator of the prognosis of tumor patients. By monitoring the expression level of ARL10, the progress and drug resistance of tumor treatment can be detected in a timely manner, providing guidance for individualized treatment of tumor patients.

in conclusion

ARL10 has a high potential role in tumor treatment and has broad application prospects as a drug target. By inhibiting the phosphorylation activity of ARL10, the role of ARL10 in tumor treatment can be inhibited and provide better therapeutic effects for tumor patients. In addition, the expression level of ARL10 can also be used as an important indicator of tumor treatment effect and prognosis. Therefore, ARL10 has great application value as a biomarker in tumor treatment.

Protein Name: ADP Ribosylation Factor Like GTPase 10

The "ARL10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets